Sapphire Therapeutics, Cytochroma, Xtent and WuXi PharmaTech - People on the move
all had people on the move in the world of pharmaceutical
manufacturing.
Sapphire Therapeutics has recently announced promotions and a new addition to the firm, as the company pushes forward with regulatory filings for its small molecule therapies. Eleanor de Groot has been promoted to vice president of technical operations, with increased responsibilities for all drug development and manufacturing activities at the company. De Groot joined the company five years ago following positions at Guildford Pharmaceuticals and the Shell Chemical Company. Brenda Marczi will also be joining Sapphire, in the role of vice president, regulatory affairs. Marczi has extensive experience in regulatory matters, and previously held senior positions at Unigene Laboratories, Baxter Healthcare, Berlex and Schering-Plough. Richard Nelson has also been promoted to vice president of project planning and management at the company. Cytochroma, a speciality pharma dedicated to developing products for the treatment of vitamin D deficiency, has landed former Abbott employee Joel Melnick to take on the role of vice president clinical and regulatory affairs. Melnick will be responsible for clinical development of the company's therapies, as well as obtaining marketing authorisations from the relevant authorities. Eli Lilly's former vice president of manufacturing, Michael Eagle, has been appointed to medical device company Xtent's board of directors, the company announced this week. Eagle has several decades' manufacturing and management experience, with eight years in his role at Lilly, preceded by positions at IVAC and Guidant. He is also a member of the board of a number of other pharmaceutical companies. WuXi PharmaTech has also been continuing its employment drive, filling three senior level positions this week, including the appointment of an executive vice president of operations at the firm. The new incumbent has been named as Edward Hu, who will take on his new role at the R&D outsourcing outfit reporting to the company CEO, Ge Li. Hu previously held positions at Tanox (recently acquired by Genentech), Biogen Idec and Merck.
